NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP

NFJ Investment Group LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 33,409 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,766,000. NFJ Investment Group LLC owned 0.15% of ANI Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Maryland State Retirement & Pension System lifted its stake in ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 200 shares during the period. Finally, Federation des caisses Desjardins du Quebec increased its holdings in shares of ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after purchasing an additional 221 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president owned 74,424 shares in the company, valued at $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ANIP has been the subject of several research analyst reports. Canaccord Genuity Group dropped their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Guggenheim decreased their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.83.

ANI Pharmaceuticals Stock Down 0.9%

ANIP opened at $77.32 on Friday. The stock has a market cap of $1.78 billion, a PE ratio of 16.66 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50. The business’s fifty day simple moving average is $80.48 and its 200 day simple moving average is $78.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The company’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.